Literature DB >> 2899186

The Northwick Park "functional" psychosis study: diagnosis and treatment response.

E C Johnstone1, T J Crow, C D Frith, D G Owens.   

Abstract

Functional psychosis is conventionally subdivided into schizophrenia and manic depressive psychosis. Response to treatment is assumed to be a validating criterion for these diagnoses. The efficacy of pimozide (a dopamine antagonist neuroleptic), lithium, and a combination of the two was compared with that of placebo in a 4 week trial in 120 functionally psychotic patients each of whom was assessed for psychotic symptoms, manic symptoms, and depressive symptoms. The sample was subdivided into patients with predominantly elevated mood, predominantly depressed mood, and no consistent mood change. Pimozide reduced psychotic symptoms in all groups of patients. The only significant effect of lithium was to reduce elevated mood. Thus dopamine blockade seems relevant to the resolution of psychotic symptoms in all types of "functional" psychosis but the mode of action of lithium in psychotic patients concerns only mood. Application of standardised classifications of functional psychosis to these data did not change this conclusion.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2899186     DOI: 10.1016/s0140-6736(88)90682-4

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  22 in total

1.  Rethinking psychosis: the disadvantages of a dichotomous classification now outweigh the advantages.

Authors:  Nick Craddock; Michael J Owen
Journal:  World Psychiatry       Date:  2007-06       Impact factor: 49.548

Review 2.  Pharmacological treatment of patients with schizophrenia. Past and present problems and potential future therapy.

Authors:  D A Johnson
Journal:  Drugs       Date:  1990-04       Impact factor: 9.546

Review 3.  Antipsychotic medication for early episode schizophrenia.

Authors:  John Bola; Dennis Kao; Haluk Soydan
Journal:  Cochrane Database Syst Rev       Date:  2011-06-15

4.  Distinguishing between schizophrenia and other psychotic disorders.

Authors:  Godfrey D Pearlson; Judith M Ford
Journal:  Schizophr Bull       Date:  2014-03-31       Impact factor: 9.306

Review 5.  The interface of clinical psychopharmacology and psychopathology.

Authors:  O Benkert; W Maier
Journal:  Eur Arch Psychiatry Neurol Sci       Date:  1989

6.  The use of atypical antipsychotics in Bipolar Spectrum disorders.

Authors:  H Grünze; H J Möller
Journal:  Indian J Psychiatry       Date:  2003-01       Impact factor: 1.759

7.  Dorsolateral prefrontal cortex dysfunction in the major psychoses; symptom or disease specificity?

Authors:  R J Dolan; C J Bench; P F Liddle; K J Friston; C D Frith; P M Grasby; R S Frackowiak
Journal:  J Neurol Neurosurg Psychiatry       Date:  1993-12       Impact factor: 10.154

Review 8.  Lithium. Current status in psychiatric disorders.

Authors:  M Peet; J P Pratt
Journal:  Drugs       Date:  1993-07       Impact factor: 9.546

9.  Schizophrenia and bipolar disorder are distinguished mainly by differences in neurodevelopment.

Authors:  Jenny Walker; Vivienne Curtis; Philip Shaw; Robin M. Murray
Journal:  Neurotox Res       Date:  2002 Aug-Sep       Impact factor: 3.911

10.  The Psychosis Continuum: Testing a Bifactor Model of Psychosis in a General Population Sample.

Authors:  Mark Shevlin; Eoin McElroy; Richard P Bentall; Ulrich Reininghaus; Jamie Murphy
Journal:  Schizophr Bull       Date:  2016-05-24       Impact factor: 9.306

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.